Kurland, B. F., Peterson, L. M., Lee, J. H., Schubert, E. K., Currin, E. R., Link, J. M., . . . Linden, H. M. (2016). Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res.

Kurland, Brenda F., Lanell M. Peterson, Jean H. Lee, Erin K. Schubert, Erin R. Currin, Jeanne M. Link, Kenneth A. Krohn, David A. Mankoff, and Hannah M. Linden. "Estrogen Receptor Binding (FES PET) and Glycolytic Activity (FDG PET) Predict Progression-free Survival On Endocrine Therapy in Patients With ER+ Breast Cancer." Clin Cancer Res 2016.

Kurland, Brenda F., et al. "Estrogen Receptor Binding (FES PET) and Glycolytic Activity (FDG PET) Predict Progression-free Survival On Endocrine Therapy in Patients With ER+ Breast Cancer." Clin Cancer Res 2016.